Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Recurrence 1Rectal Neoplasms 1Pinealoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Mammary Neoplasms, Animal 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Hodgkin Disease 1Fallopian Tube Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

imetelstat 1entinostat 1GRN163L peptide 1Everolimus 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Stem Neoplasms × entinostat × Clear all
NCT02780804 2023-10-17

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled 15 charts
CNSLymphoid

Lymphoma, Pinealoma, Central Nervous System Neoplasms, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡